Literature DB >> 7622874

Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.

J Ferbas1, A H Kaplan, M A Hausner, L E Hultin, J L Matud, Z Liu, D L Panicali, H Nerng-Ho, R Detels, J V Giorgi.   

Abstract

Persons infected with human immunodeficiency virus (HIV) for > 8 years were studied to delineate virologic and immunologic attributes of long-term survival. Whereas those with 300-700 CD4+ cells/microL often had circulating cytotoxic T lymphocytes (CTL) against HIV antigens, those with > 1000 CD4+ cells/microL did not. The subjects with > 1000 CD4+ cells/microL had low virus burden, low levels of Gag-specific CTL precursors, and minimal CD8+ cell activation. Overall, elevated levels of CD8+ cells, CD38 antigen expression on CD8+ cells, and anti-HIV functions were correlated with increased virus burden, provirus load, and HIV plasma RNA levels. A factor that suppressed HIV replication was spontaneously secreted from CD8+ cells of most subjects but not from those with high CD4+ cell counts. CD8+ cell activities, therefore, may reflect chronic viral stimulation of the immune system. Long-term survivors with high levels of CD4+ cells maintained control of viral replication but lacked the CD8+ cell activities.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622874     DOI: 10.1093/infdis/172.2.329

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen.

Authors:  J C de Quiros; W L Shupert; A C McNeil; J C Gea-Banacloche; M Flanigan; A Savage; L Martino; E E Weiskopf; H Imamichi; Y M Zhang; J Adelsburger; R Stevens; P M Murphy; P A Zimmerman; C W Hallahan; R T Davey; M Connors
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable.

Authors:  K S Froebel; G M Raab; C D'Alessandro; M P Armitage; K M MacKenzie; M Struthers; J M Whitelaw; S Yang
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

3.  Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?

Authors:  D R Bainbridge; M W Lowdell; I M Hannet; K W Strauss; A Karpas
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-07-29       Impact factor: 6.237

4.  Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells.

Authors:  O O Yang; A C Tran; S A Kalams; R P Johnson; M R Roberts; B D Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 5.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

Review 6.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

7.  Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection.

Authors:  J Ferbas; E S Daar; K Grovit-Ferbas; W J Lech; R Detels; J V Giorgi; A H Kaplan
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

8.  In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.

Authors:  W J Lech; G Wang; Y L Yang; Y Chee; K Dorman; D McCrae; L C Lazzeroni; J W Erickson; J S Sinsheimer; A H Kaplan
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.

Authors:  L Deml; A Bojak; S Steck; M Graf; J Wild; R Schirmbeck; H Wolf; R Wagner
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes.

Authors:  Leslie E Walker; Lo Vang; Xuefei Shen; Brian D Livingston; Penny Post; Alessandro Sette; C Steven Godin; Mark J Newman
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.